U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1449

	Ta _ =
Sheet1 (
	- 8 = 1
	390

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 16952CON1DIV8	SERIAL NO.: PENDING
APPLICANT: AOKI ET AL	TITLE: METHOD FOR TREATING DYSTONIA WITH BOTULINUM TOXIN TYPE B
FILING DATE: SUBMITTED HEREWITH	GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
- <i>H</i> /k	AA	2373454	4/45	BUMY ET AL			
4	AB	3132995	5/64	BERGER ET AL			
410	AC	4713240	12/87	WILKINS ET AL			
4	AD	4432936	6/90	DYSTRA ET AL			
- 40	AE	5056291	10/91	EAM ET AL			
4	AF	5055302	10/91	LATIES ET AL			
	AG	5053005	10/91	BORODIC			
	AH	5183462	2/93	BORODIC			_
/ /// -	AI	2719102	9/55	BALDWIN			
40	AJ	5766605	6/98	SANDERS ET AL			
A	AK	5437291	8/95	PASRICHA ET AL			

FOREIGN PATENT DOCUMENTS

.,		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
9	AL	95/28171	PCT				

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)


14	_ AM	CORRESPONDENCE DATED 12/10/91 BETWEEN WILLIAM C. SHEPHERD AND IRA
X		SANDERS
	AN	CORRESPONDENCE DATED 4/13/92 BETWEEN IRA SANDERS AND ANGELIKA S.
İ		ASWAD REGARDING "ANIMAL STUDY"
	AO	PARTIAL CORRESPONDENCE DATED 4/24/92 BETWEEN ANGELIKA S. ASWAD
	į	AND DR. SANDERS REGARDING "BOTULINUM TOXIN TO DECREASE SALIVARY
		FLOW"
	AP	AMBACHE, J. PHYSIOL. (1951) 113, 1-17.
	AQ	AMBACHE, J. PHYSIOL. (1949) 108, 127-141.
	AR	BRIN; ARCH. DE NEUROBIOL. 54. SUPL. 3 (7-23) 1991.
	AS	JENZER ET AL; SCHWEIZ. MED. WSCHR. (1974); 104, 685-693 (w/ English translation).
₩	AT	POUNGVARIN ET AL; J. MED. ASSOC. THAI. (1992 Apr) 75 (4) 199-203.

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1449



SUPPLEMENTAL LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 16952CON1DIV8	SERIAL NO.: 09/490,756
APPLICANT: AOKI ET AL	TITLE: METHOD FOR TREATING DYSTONIA WITH BOTULINUM TOXIN TYPE B
FILING DATE: 01/24/00	GROUP: 1653

U.S. PATENT DOCUMENTS

*EXAMINER INMIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
X	AA	5,298,019	3/1994	Borodic			
47	AB	5,401,243	3/1995	Borodic			
8/1	AC	5,696,077	12/1997	Johnson et al.			
/	AD						
	AE					L	

FOREIGN PATENT DOCUMENTS

11		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
M	BA	94/00481	1/1994	PCT			
1	BB						
	BC					,	

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

			(Including Nation, Title, Eate, Fertiment Lager, 1997)
		CA	
XV	$1 \le 1$		Resistant Patients; Movement Disorders; Vol. 11, No. 2; pp. 181-184 (March 1996).
		СВ	
	\		Nonhuman Primates; Botulinum and Tetanus Neurotoxins—Neurotransmission and
			Biomedical Aspects; Bibhuti R. Dasgupta, Editor; Plenum Press (1993).
		CC	Price, J., et al.; A Comparative-Study of Tear Secretion in Blepharospasm and Hemifacial
			Spasm Patients Treated with Botulinum Toxin; Journal of Clinical Neuro-Ophthalmology;
			Vol. 13, No. 1; pp. 67-71 (March 1993). Abstract only.
	1	CD	Scott, Alan B., et al.; Systemic Toxicity of Botulinum Toxin by Intramuscular Injection in the
			Monkey; Movement Disorders; Vol. 3, No. 4; pp. 333-335 (1988).
	1	CE	Truong, Daniel D., et al.; BotB (Botulinum Toxin Type B): Evaluation of Safety and
4	7		Tolerability in Botulinum Toxin Type A-Resistant Cervical Dystonia Patients (Preliminary
/\	<i>U</i> Y		Study); Movement Disorders; Vol. 12, No. 5; pp. 772-775 (Sep 1997).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference	considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not i
conformance and not considered.	nclude copy of this form with next communication to applicant.

Sheet <u>2</u> of <u>2</u>

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1449

SUPPLEMENTAL LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 16952CON1DIV8	SERIAL NO.: 09/490,756
APPLICANT: AOKI ET AL	TITLE: METHOD FOR TREATING DYSTONIA WITH BOTULINUM TOXIN TYPE B
FILING DATE: 01/24/00	GROUP: 1653

OTHER ART (Continued)

(Including Author, Title, Date, Pertinent Pages, etc.)

	1	CF	Tsui, J.K., et al.; A Pilot Study on the Use of Botulinum Toxin in Spasmodic Torticollis; The
L	M		Canadian Journal of Neurological Sciences; Vol. 12, No. 4; pp. 314-316 (Nov 1985).
ĺ	7	CG	Tsui, Joseph K.C., et al.; Local Treatment of Spasmodic Torticollis with Botulinum Toxin; Le
l			Journal Canadien des Sciences Neurologiques; Vol. 14, No. 3 (Supplement); pp. 533-535
l			(August 1987).
ŀ		СН	Med Ad News staff; Athena Makes a Wise Move; Medical Advertising News; page 4
			(November 1992).
ŀ	LIA	CI	U.S. Food and Drug Administration; List of Orphan Designations and Approvals; pp. 1 and
	$\triangleleft M$		42-46 of 275 (computer search printout dated Jan. 18, 2000).
ŀ	- / V-	CJ	
İ			
ŀ		CK	
İ		CI	
ŀ		CI	
I		CL	
ļ			
١		CM	
l			
I		CN	
]		
		CO	
		CP	
		1	
		CQ	
	1		

EXAMINER		D.	ATE (CONSIDERED
	 	 	r	in MADED (00) Down the sharesh situation if no

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TO DEMARK OFFICE FORM PTO-1449

DEC. 2 3 7000



DEC 3 1 2002

OF ART CITED BY APPLICANT

	ED DI AFFEICANI
ATTY. DOCKES 186952 CON1DIV8DIV5 (BOT)	SERIAL NO.: 09/904,057 EUH UENTEH 1600/2900
APPLICANT: AOKI, et al.	TITLE: METHODS FOR TREATING MUSCLE SPASM WITH BOTULINUM TOXIN TYPE B
FILING DATE: July 11, 2001	GROUP: 1653

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME (JOHNSON)	CLASS	SUB-CLASS	FILING DATE (if applicable)
11/4	AA	5,696,077	12/9/97	Goodnough, et al.			
7—	AB						
	AC		-				
	AD						
	AE						

FOREIGN PATENT DOCUMENTS

,,,		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BB	WO 94/0081A	06 Jan 94	PCT			
4/		WO 94/28922	22 Dec 94	PCT			

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

	– CA	Borodic, G.E., et al., <i>Botulinum B Toxin as an alternative to Botulinum A Toxin: A Histologic Study</i> , Ophthalmic Plastic and Reconstructive Surgery, Vol. 9, No. 3, pp 182-190, 1993
1	→ CB	Schantz, E.J., et al., <i>Properties and use of botulinum toxin and other microbial neurotoxins in medicine</i> , Microbiological Reviews, Mar. 1992, pp. 80-99, Vol. 56, No. 1
	CC	Sellin, L.C., et al., Different effects of types A and B botulinum toxin on transmitter release at the rat neuromuscular junction, Acta Physiolo Scand 1983, 119:127-133
	CD	
	CE	

EXAMINER	DATE CONSIDERED	
EXAMINER	DATE CONSIDERED	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.